Pfizer, EMD Terminate Bavencio Head, Neck Cancer Trial
March 13 2020 - 9:26AM
Dow Jones News
By Colin Kellaher
Pfizer Inc. and Merck KGaA's EMD Serono unit on Friday said they
are ending a Phase III study of the immunotherapy Bavencio in head
and neck cancer because it was unlikely to meet its primary
endpoint.
The companies said the study evaluating Bavencio in addition to
chemoradiotherapy, the standard of care, in patients with untreated
locally advanced squamous cell carcinoma of the head and neck, was
unlikely to show a statistically significant improvement in
progression-free survival based on a preplanned interim
analysis.
Pfizer and EMD said they have accepted the recommendation of the
study's independent data monitoring committee to terminate the
trial.
Germany's Merck and New York-based Pfizer formed a strategic
alliance in 2014 to jointly develop and commercialize Bavencio. The
drug is currently approved in 50 countries for patients with the
skin cancer Merkel cell carcinoma.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 13, 2020 09:11 ET (13:11 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Apr 2023 to Apr 2024